Researchers Develop Experimental Cream for Inflammatory Skin Conditions

Early studies show a compound suppressing mast cells could provide relief for rosacea, eczema, and other skin disorders.

The compound SYM2081, tested in mice and human skin samples, effectively reduces inflammation by targeting overactive mast cells.
Mast cells, which release histamines and other inflammatory agents, are key drivers of symptoms like redness, swelling, and itching in skin conditions.
SYM2081 activates the GluK2 receptor on mast cells, calming their activity and reducing skin inflammation in conditions such as rosacea and eczema.
Researchers at the University of Pittsburgh have applied for a patent and plan to develop new compounds for potential clinical trials in humans.
If successful, this approach could address unmet needs, including rosacea-associated flushing, which current treatments fail to adequately target.